Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Amino Acids ; 54(10): 1357-1369, 2022 Oct.
Article in English | MEDLINE | ID: mdl-34642825

ABSTRACT

Weaning is a challenging period for gut health in piglets. Previous studies showed that dietary supplementations with either amino acids or polyphenols promote piglet growth and intestinal functions, when administered separately. Thus, we hypothesized that a combination of amino acids and polyphenols could facilitate the weaning transition. Piglets received during the first two weeks after weaning a diet supplemented or not with a mix of a low dose (0.1%) of functional amino acids (L-arginine, L-leucine, L-valine, L-isoleucine, L-cystine) and 100 ppm of a polyphenol-rich extract from grape seeds and skins. The mix of amino acids and polyphenols improved growth and feed efficiency. These beneficial effects were associated with a lower microbiota diversity and a bloom of Lactobacillaceae in the jejunum content while the abundance of Proteobacteria was reduced in the caecum content. The mix of amino acids and polyphenols also increased the production by the caecum microbiota of short-chain fatty acids (butyrate, propionate) and of metabolites derived from amino acids (branched-chain fatty acids, valerate, putrescine) and from polyphenols (3-phenylpropionate). Experiments in piglet jejunum organoids revealed that the mix of amino acids and polyphenols upregulated the gene expression of epithelial differentiation markers while it reduced the gene expression of proliferation and innate immunity markers. In conclusion, the supplementation of a mix of amino acids and polyphenols is a promising nutritional strategy to manage gut health in piglets through the modulation of the gut microbiota and of the epithelial barrier.


Subject(s)
Gastrointestinal Microbiome , Vitis , Swine , Animals , Animal Feed/analysis , Polyphenols/pharmacology , Amino Acids/pharmacology , Organoids , Weaning , Dietary Supplements , Homeostasis
2.
PLoS One ; 7(11): e49547, 2012.
Article in English | MEDLINE | ID: mdl-23166707

ABSTRACT

Pro-inflammatory cytokines like macrophage migration inhibitory factor (MIF), IL-1ß and TNF-α predominate in inflammatory bowel diseases (IBD) and TNBS colitis. Increased levels of serine proteases activating protease-activated receptor 2 (PAR-2) are found in the lumen and colonic tissue of IBD patients. PAR-2 activity and pro-inflammatory cytokines impair epithelial barrier, facilitating the uptake of luminal aggressors that perpetuate inflammation and visceral pain. Soy extracts contain phytoestrogens (isoflavones) and serine protease inhibitors namely Bowman-Birk Inhibitors (BBI). Since estrogens exhibit anti-inflammatory and epithelial barrier enhancing properties, and that a BBI concentrate improves ulcerative colitis, we aimed to evaluate if a fermented soy germ extract (FSG) with standardized isoflavone profile and stable BBI content exert cumulative or synergistic protection based on protease inhibition and estrogen receptor (ER)-ligand activity in colitic rats. Female rats received orally for 15 d either vehicle or FSG with or without an ER antagonist ICI 182.780 before TNBS intracolonic instillation. Macroscopic and microscopic damages, myeloperoxidase activity, cytokine levels, intestinal paracellular permeability, visceral sensitivity, faecal proteolytic activity and PAR-2 expression were assessed 24 h, 3 d and 5 d post-TNBS. FSG treatment improved the severity of colitis, by decreasing the TNBS-induced rise in gut permeability, visceral sensitivity, faecal proteolytic activity and PAR-2 expression at all post-TNBS points. All FSG effects were reversed by the ICI 182.780 except the decrease in faecal proteolytic activity and PAR-2 expression. In conclusion, the anti-inflammatory properties of FSG treatment result from two distinct but synergic pathways i.e an ER-ligand and a PAR-2 mediated pathway, providing rationale for potential use as adjuvant therapy in IBD.


Subject(s)
Feces/enzymology , Glycine max/chemistry , Hyperalgesia , Inflammatory Bowel Diseases/metabolism , Intestinal Mucosa/metabolism , Peptide Hydrolases/metabolism , Plant Extracts/administration & dosage , Animals , Cytokines/metabolism , Disease Models, Animal , Enzyme Activation/drug effects , Female , Humans , Hyperalgesia/therapy , Inflammatory Bowel Diseases/chemically induced , Inflammatory Bowel Diseases/therapy , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Permeability/drug effects , Rats , Receptor, PAR-2/metabolism , Trinitrobenzenesulfonic Acid/adverse effects , Weight Loss/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL